Olaparib Induced Senescence is Bypassed through G2/M Checkpoint Override in Olaparib Resistant Prostate Cancer.
PARP inhibition represents the dawn of precision medicine for treating prostate cancer. Despite this advance, questions remain regarding the use of PARP inhibitors (PARPi’s) for the treatment of this disease, including 1) how specifically do PARPi sensitive tumor cells respond to treatment, and 2) how does PARPi resistance develop? To address these questions, we characterized […]